Aarti Drugs Limited
Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2024-25/132
February 14, 2025

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
"Exchange Plaza", Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Update on lifting of Import Alert 66-40 by US FDA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to the intimation given by the Company dated September 20, 2024, September 25, 2024 on inspection at API manufacturing facility of the Company at Plot No-E-22, MIDC, Tarapur, Maharashtra by United States Food and Drug Administration (US FDA) and intimation dated December 24, 2024 on receipt of EIR (Establishment Inspection Report) for the aforesaid facility.

We bring to your notice that the Company is in receipt of the letter from the US FDA informing that Aarti Drugs Limited is no longer subject to refusal of admission and has been removed from Import Alert 66-40.

The information as per Para A of Part A of Schedule III under Regulation 30 of the Listing Regulations is given below:

Name of the Authority	United States Food and Drug Administration (US FDA)
Nature and details of the action(s) taken, initiated or order(s) passed	United States Food and Drug Administration (US FDA) has reviewed the Form FDA 483 and establishment inspection report (EIR) and Company's response to the Form FDA 483 pertaining to the inspection conducted at API manufacturing facility of the Company located at Plot No. E-22, MIDC, Tarapur, Maharashtra from September 12 to September 20, 2024. US FDA have determined from their review that Aarti Drugs Limited is no longer subject to refusal of admission and has been removed from Import Alert 66-40.

Aarti Drugs Limited
Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	February 14, 2025
Details of the violation(s) / contravention(s) committed or alleged to be committed	There is no violation(s) / contravention(s) committed or alleged to be committed
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There are no financial or material impacts as on date. US FDA has lifted the Import Alert 66-40. Due to this Company can export the products such as Ciprofloxacin HCl API, Zolpidem Tartrate API, Raloxifene HCl API, Celecoxib API and Niacin API in US Market.

You are requested to take this reply on records.

Thanking you,

Yours faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH VIVEK DEOLE

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932